Loading…
Alzamend Neuro, Inc. is projected to decline to $1.32 by 2027, a -2% move from its current price of $1.34. ALZN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.30 | $1.34 | $1.38 | 0.00% |
| Aug 6 | $1.28 | $1.34 | $1.40 | 0.00% |
| Aug 7 | $1.27 | $1.34 | $1.42 | 0.00% |
| Aug 8 | $1.26 | $1.34 | $1.43 | 0.00% |
| Aug 9 | $1.25 | $1.34 | $1.44 | 0.00% |
| Aug 10 | $1.24 | $1.34 | $1.45 | 0.00% |
| Aug 11 | $1.23 | $1.34 | $1.46 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.23 | $1.34 | $1.46 | 0.00% |
| Week 2 | $1.19 | $1.34 | $1.51 | +0.01% |
| Week 3 | $1.16 | $1.34 | $1.55 | +0.01% |
| Week 4 | $1.13 | $1.34 | $1.59 | +0.02% |
| Week 5 | $1.11 | $1.34 | $1.62 | +0.02% |
| Week 6 | $1.09 | $1.34 | $1.65 | +0.02% |
| Week 7 | $1.07 | $1.34 | $1.67 | +0.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and psychiatric disorders.
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient\'s immunological system to combat Alzheimer\'s disease.
Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc. (ALZN) is currently priced at $1.32 per share and has a market capitalization of $5.02M, with a market rank of 5249.
The company operates within the Healthcare sector and has a pipeline that includes AL001 and ALZN002.
Forecasts show a multi-year price path, with an average price of $1.29 by 2030 and $3.79 by 2050, including a max of $7.59 in 2050. The 2040 forecast shows an average of $1.83 with a max of $3.30, while 2030 features an average of $1.29 and a max of $1.96. Overall, sentiment shifts toward bullish in the longer term (2040+), with earlier years shown as neutral.
A major floor 36.0% below — a decisive break under it would weaken the trend.
The nearest floor, 16.4% below — buyers have tended to step in here.
Price is pressing into resistance (2.2% away) — a breakout level to watch.
A major ceiling 44.0% above — clearing it would confirm fresh momentum.
Key ALZN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALZN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.33 | Buy | $1.32 | Buy |
| MA 10 | $1.32 | Buy | $1.31 | Buy |
| MA 20 | $1.25 | Buy | $1.27 | Buy |
| MA 50 | $1.21 | Buy | $1.24 | Buy |
| MA 100 | $1.24 | Buy | $1.36 | Sell |
| MA 200 | $1.71 | Sell | $2.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.69 | Neutral |
| Stoch RSI (14) | 24.55 | Neutral |
| CCI (20) | 59.75 | Neutral |
| Williams %R (14) | -28.57 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 6.50 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 71.43 | Neutral |
| TRIX (15) | 0.37 | Buy |
| Awesome (5,34) | 0.09 | Buy |
| Ultimate (7,14,28) | 50.70 | Neutral |
| Momentum (10) | 0.10 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 1.34 | Buy |
| ADX (14) | 14.32 | Neutral |
| ATR (14) | 0.04 | Info |
Current technical sentiment is BULLISH. RSI(14) is 60, suggesting neutral-to-positive momentum. The 50-day simple moving average (SMA50) is $1.17 and the 200-day simple moving average (SMA200) is $1.75. The 30-day range is $1.06–$1.65, with support at $1.12 and resistance at $1.37.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.858 | $1.34 | $1.67 | 0% | Neutral | |
| $1.04 | $1.32 | $1.78 | -2% | Neutral | |
| $0.9703 | $1.28 | $1.80 | -5% | Neutral | |
| $0.8399 | $1.14 | $1.66 | -15% | Bearish | |
| $0.9535 | $1.32 | $1.98 | -1% | Neutral | |
| $1.11 | $1.58 | $2.42 | +18% | Neutral | |
| $1.08 | $1.56 | $2.45 | +17% | Neutral | |
| $1.08 | $1.60 | $2.57 | +20% | Neutral | |
| $0.9662 | $1.45 | $2.37 | +9% | Neutral | |
| $0.9505 | $1.46 | $2.41 | +9% | Neutral | |
| $1.14 | $1.90 | $3.37 | +42% | Bullish | |
| $1.95 | $3.75 | $7.36 | +180% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.858 | $1.34 | $1.58 | +0.00% |
| September 2026 | $1.13 | $1.34 | $1.64 | -0.03% |
| October 2026 | $1.12 | $1.34 | $1.66 | +0.09% |
| November 2026 | $1.08 | $1.30 | $1.63 | -2.95% |
| December 2026 | $1.09 | $1.32 | $1.67 | +1.73% |
Click any year to see its month-by-month ALZN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ALZN is projected to trade between $0.858 and $1.67, averaging $1.34 — a potential gain of 0% from today's $1.34. Price action looks broadly range-bound.
Alzamend Neuro, Inc.'s 2027 outlook centres on $1.32, within a $1.04 to $1.78 range. That is -2% versus the projected 2026 average. That marks a -2% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, ALZN could reach as high as $1.80, with a base case around $1.28 and support toward $0.9703 — roughly -5% from $1.34. Price action looks broadly range-bound.
Expect ALZN to range from $0.8399 to $1.66 through 2029. The $1.14 average target implies a -15% move from current prices. That is -11% versus the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
The ALZN price prediction for 2030 points to an average of $1.32 (low $0.9535, high $1.98) — a potential decline of -1% on today's $1.34. Price action looks broadly range-bound.
In 2031, ALZN is projected to trade between $1.11 and $2.42, averaging $1.58 — a potential gain of +18% from today's $1.34. That is up +19% on the projected 2030 average. A consolidation phase looks the most probable path here.
Alzamend Neuro, Inc.'s 2032 outlook centres on $1.56, within a $1.08 to $2.45 range. That is -1% versus the projected 2031 average. That marks a +17% change versus current levels. Price action looks broadly range-bound.
By 2033, ALZN could reach as high as $2.57, with a base case around $1.60 and support toward $1.08 — roughly +20% from $1.34. A consolidation phase looks the most probable path here.
Expect ALZN to range from $0.9662 to $2.37 through 2034. The $1.45 average target implies a +9% move from current prices. That is -9% versus the projected 2033 average. Price action looks broadly range-bound.
The ALZN price prediction for 2035 points to an average of $1.46 (low $0.9505, high $2.41) — a potential gain of +9% on today's $1.34. A consolidation phase looks the most probable path here.
In 2040, ALZN is projected to trade between $1.14 and $3.37, averaging $1.90 — a potential gain of +42% from today's $1.34. That is up +30% on the projected 2035 average. Momentum favours further upside here.
Alzamend Neuro, Inc.'s 2050 outlook centres on $3.75, within a $1.95 to $7.36 range. That is up +98% on the projected 2040 average. That marks a +180% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALZN today (≈ 746.268657 ALZN) could be worth
$2,800.43
+$1,800.43 (+180%) by 2050 · US Dollar
Based on the average projected ALZN price of $3.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALZNwould be worth at today's price.
$1,000 invested in ALZN on Jul 31, 2025 (≈ 444.444444 ALZN) would be worth
$595.56
-$404.44 (-40.4%) today · 0.60× · US Dollar
Based on a ALZN entry price of $2.25 vs. today's $1.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.33 | $1,007.52 | +0.8% |
| 1 month ago | $1.12 | $1,196.43 | +19.6% |
| 3 months ago | $1.12 | $1,196.43 | +19.6% |
| 6 months ago | $2.17 | $617.51 | -38.2% |
| 1 year ago | $2.25 | $595.56 | -40.4% |
| All time (5.0y) ago | $5,697 | $0.24 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALZN forecast.
Our base-case forecast reaches $2.70 around 2050.
Implied market cap at $2.70: $12.94M
Looking across the multi-year forecast, the asset shows a path of gradual upside with notable milestones. The 2030 forecast gives an average price of $1.29 with a max of $1.96 and a min of $0.9202, reflecting a -2.2% ROI in that year and a NEUTRAL sentiment. From 2031 to 2033, the averages are around $1.56–$1.55 with max prices near $2.42–$2.52 and ROI around 17.9–17.5%, maintaining NEUTRAL sentiment.
The forecast then projects stronger upside by 2040, with an average of $1.83 and a max of $3.30, ROI at 38.4% and a shift to BULLISH sentiment. By 2050, the average is $3.79 and the max $7.59, with an ROI of 187% and a BULLISH sentiment.
These figures are estimates and not guarantees, and risk regions include years with negative ROIs (for example 2027 at -2.5%, 2028 at -6.7%, and 2029 at -14.7%). The outlook should be considered in the context of the provided numbers and accompanying uncertainties.
Tap a question to reveal the answer.
Average price $1.29, min $0.9202, max $1.96 with ROI -2.2% and sentiment NEUTRAL.
Forecasts show a range of outcomes. The 2030 average is $1.29 with ROI -2.2% (NEUTRAL), while the 2050 forecast shows an average of $3.79 with ROI 187% (BULLISH). There are years with negative ROIs (e.g., 2027 -2.5%, 2028 -6.7%, 2029 -14.7%), so outcomes are uncertain.
The forecast max prices reach $2.42 in 2031 and $2.48 in 2032 and $2.52 in 2033, with higher maxes later (e.g., $3.30 in 2040 and $7.59 in 2050).
Current price $1.32; Market cap $5.02M.
30-day range is $1.06 to $1.65.
Alzamend Neuro, Inc. Community Discussion
0Share your Alzamend Neuro, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.